EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Foscarnet Versus Ganciclovir for Severe Congenital Cytomegalovirus Infection: Short- and Long-Term Follow-Up

Giovanni Nigro iD, Marta Buzzi, Milena Catenaro, Eleonora Coclite, Mario Muselli

Viruses · 2025

DOI: 10.3390/v17050720 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Viruses, 2025. Verfasst von Giovanni Nigro und 4 weiteren Autor:innen. Beteiligte Einrichtung: Non-Profit Association Mother-Infant Cytomegalovirus Infection (AMICI), 00042 Rome, Italy. Hauptthemen laut MEDLINE: Antiviral Agents, Cytomegalovirus Infections, Foscarnet, Ganciclovir. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytomegalovirus (CMV) infection is the most common and serious congenital infection, with universal screening in pregnancy, standardized therapy, and a vaccine still lacking. Study design: In the 1990s, we noted that intravenous ganciclovir did not cure some children with severe sequelae due to congenital cytomegalovirus (CMV) infection. Therefore, we performed an open randomized trial using intravenous foscarnet as an alternative to intravenous ganciclovir in 24 infants (12 in each therapy group), all with severe neurological manifestations due to congenital CMV infection. Nine and five infants, belonging to the foscarnet or ganciclovir group, respectively, had abnormal hearing. One infant in each group also had chorioretinitis. Concomitantly, 12 CMV-infected infants with similar manifestations, who did not receive any therapy, were used as controls. The results of short-term (2 years) and long-term (7–29 years, mean 22.2) follow-up are reported herein. Short-term results: Neurological outcomes were normal in five of the twelve children who were treated with foscarnet, compared to nine of the twelve children given ganciclovir. None of the untreated children were healthy. There was a statistically significant difference (p = 0.023) between the treated and untreated children. Hearing was normal in four of the twelve children treated with foscarnet, seven of the twelve children treated with ganciclovir, and two untreated children. Long-term-results: Two children in both therapy groups died before the age of 17 years, and six untreated children died between 7 and 26 years of age. Neurological outcomes were normal in three of the ten children treated with foscarnet, in two of the ten treated with ganciclovir, and in none of the untreated children. Hearing was normal in two children treated with foscarnet, in six children treated with ganciclovir, and in one untreated child.

Conclusions

Intravenous ganciclovir and foscarnet were found to be safe at long-term follow-up and appeared to be capable of mitigating the neurological and auditory consequences of congenital CMV disease at the short-term follow-up. However, there was progressive worsening of the symptomatology in all three groups, with a statistically significant increase in the number of deaths (p = 0.035) among 4 of the 24 children in the therapy groups and 6 of the 12 untreated children.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCytomegalovirus InfectionsFoscarnetGanciclovirAdolescentAdultChildChild, PreschoolFemaleHumansInfantInfant, NewbornMalePregnancyYoung AdultCytomegalovirusFollow-Up StudiesTreatment Outcome

Stichwörter der Autor:innen

congenital cytomegalovirus infectionencephalopathyfoscarnetganciclovirsensorineural hearing loss

Substanzen

Antiviral AgentsFoscarnetGanciclovir

Autor:innen und Institutionen

  • Non-Profit Association Mother-Infant Cytomegalovirus Infection (AMICI), 00042 Rome, Italy.
  • Azienda Sanitaria Locale, 66100 Chieti, Italy.
  • Pediatric Department, Santo Spirito Hospital, 65121 Pescara, Italy.
  • Azienda Sanitaria Locale, 64100 Teramo, Italy.
  • Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.

ORCID-Profile: Giovanni Nigro

Zitieren

APA

Nigro, G., Buzzi, M., Catenaro, M., Coclite, E., & Muselli, M. (2025). Foscarnet Versus Ganciclovir for Severe Congenital Cytomegalovirus Infection: Short- and Long-Term Follow-Up. Viruses. https://doi.org/10.3390/v17050720

Vancouver

Nigro G, Buzzi M, Catenaro M, Coclite E, Muselli M. Foscarnet Versus Ganciclovir for Severe Congenital Cytomegalovirus Infection: Short- and Long-Term Follow-Up. Viruses. 2025. doi:10.3390/v17050720

BibTeX
@article{Nigro2025,
  author = {Nigro, Giovanni and Buzzi, Marta and Catenaro, Milena and Coclite, Eleonora and Muselli, Mario},
  title = {Foscarnet Versus Ganciclovir for Severe Congenital Cytomegalovirus Infection: Short- and Long-Term Follow-Up},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17050720}
}
Kostenlos starten →